Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & DiagnosticfiledCriticalNovartis Vaccines & Diagnostic
Priority to ARP070103843priorityCriticalpatent/AR062591A1/en
Publication of AR062591A1publicationCriticalpatent/AR062591A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Sales de benzimidazolil piridil éteres, en particular sales de {1-metil-5-[2-(5-trifluorometil-1H-imidazol-2-il)-piridin-4-iloxi]-1H-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina. Se proveen composiciones y formulaciones que incluyen dichas sales y agentes tensioactivos, así como métodos para preparar tales composiciones y formulaciones.Salts of benzimidazolyl pyridyl ethers, in particular salts of {1-methyl-5- [2- (5-trifluoromethyl-1H-imidazol-2-yl) -pyridin-4-yloxy] -1H-benzoimidazol-2-yl} - (4-trifluoromethyl-phenyl) amine. Compositions and formulations are provided which include said salts and surfactants, as well as methods for preparing such compositions and formulations.
ARP0701038432007-08-292007-08-29
STERNS OF BENZIMIDAZOLIL PIRIDIL ETERES AND FORMULATIONS CONTAINING THEM
AR062591A1
(en)
Compounds derived from heterocyclyl pyridinyl, with 5-ht6 receptor modulating activity; pharmaceutical composition that comprises them and their use to treat schizophrenia, anxiety, migraine, depression, among others.